Human epidermal growth factor receptor 2/neu overexpression in urothelial carcinoma of the bladder and its prognostic significance: Is it worth hype?
Autor: | Omprakash Prajapati, Santosh Kumar, A S Sriharsha, S. K. Singh, Kim Vaiphei, Kalpesh Parmar |
---|---|
Rok vydání: | 2016 |
Předmět: |
Cancer Research
Pathology medicine.medical_specialty Urinary bladder medicine.drug_class business.industry C-erbB2 gene lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Monoclonal antibody GENITOURINARY: Original Article lcsh:RC254-282 Metastasis Staining Transitional cell carcinoma medicine.anatomical_structure Oncology urothelial cancer immunohistochemistry medicine Immunohistochemistry Lymph business Human Epidermal Growth Factor Receptor 2 human epidermal growth factor receptor 2/neu |
Zdroj: | South Asian Journal of Cancer South Asian Journal of Cancer, Vol 4, Iss 3, Pp 115-117 (2015) |
ISSN: | 2278-330X |
Popis: | Aims: In urothelial tumors of the urinary bladder, human epidermal growth factor receptor 2 (HER-2)/neu expression has been reported over 10 years, but there is no clear correlation between prognosis and recurrence rate. The present study evaluates prognostic implication of HER-2/neu expression. Subjects and Methods: In this study, 100 formalin-fixed paraffin-embedded specimens of primary transitional cell carcinoma of the bladder were processed. HER-2/neu monoclonal antibody immunohistochemistry staining procedure used for the study. Results: A total of 70 (70%) patients were positive for overexpression of HER-2/neu. HER-2/neu was positive in patients with 42 (70%) superficial tumor, 28 (70%) muscle invasive tumor, 41 (75.9%) high-grade tumor, 29 (63%) low grade tumor, 31 (68.9%) recurrent tumor, and 6 (66.6%) had positive lymph nodes. Conclusions: Human epidermal growth factor receptor 2/neu over expression was not correlated with the tumor stage, lymphnode metastasis or recurrence of the disease. HER-2/neu overexpression was statistically insignificantly correlated with the differentiation grade (P < 0.161) as compared to previous studies. Future studies on HER-2 expression with chemo-sensitivity and efficacy of HER-2-targeted therapies in urothelial carcinomas is needed. |
Databáze: | OpenAIRE |
Externí odkaz: |